Avadel Pharmaceuticals plc (AVDL)

Market Cap	915.08M
Revenue (ttm)	194.45M
Net Income (ttm)	-26.41M
Shares Out	96.63M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	40.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,811,798
Open	9.74
Previous Close	8.64
Day's Range	8.85 - 9.98
52-Week Range	6.38 - 17.85
Beta	1.63
Analysts	Strong Buy
Price Target	18.86 (+99.16%)
Earnings Date	May 7, 2025

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 7, 1996
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: AVDL
• Website: https://www.avadel.com

Financial Performance

In 2024, Avadel Pharmaceuticals's revenue was $169.12 million, an increase of 504.79% compared to the previous year's $27.96 million. Losses were -$48.83 million, -69.53% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price forecast is $18.86, which is an increase of 99.16% from the latest price.

Price Target

$18.86

(99.16% upside)

Analyst Consensus: Strong Buy